REGNRegeneron PharmaceuticalsSigning up patients
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 2
- Patients
- 397 (planned)
- Started
- May 28, 2025
- Main results expected
- Jun 30, 2028
- Fully finished
- Jun 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by investigator assessment
Measured over: Up to 3 years
Changes Tremor has spotted
Raised the number of patients from 297 to 397.
Spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- 2026-11-06 15:29 UTC · enrollment_increased · enrollment
old: 297
new: 397
details: {"new_type":"ESTIMATED","old_type":"ESTIMATED"}
Trial ID NCT06787612 · record last updated 2026-11-06 · checked 2026-11-09 15:36 UTC